Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Skinvisible (SKVI) EBITDA Margin (2016 - 2025)

Skinvisible's EBITDA Margin history spans 16 years, with the latest figure at 2121.14% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 37824.0% year-over-year to 2121.14%; the TTM value through Sep 2025 reached 2904.44%, down 26753.0%, while the annual FY2024 figure was 2947.94%, 49607.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 2121.14% at Skinvisible, up from 2724.74% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 55.56% in Q2 2021 and bottomed at 3974.86% in Q4 2024.
  • The 5-year median for EBITDA Margin is 2262.2% (2023), against an average of 1784.34%.
  • The largest annual shift saw EBITDA Margin surged 282876bps in 2021 before it crashed -242547bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 23.34% in 2021, then plummeted by -10188bps to 2354.32% in 2022, then decreased by -16bps to 2730.76% in 2023, then plummeted by -46bps to 3974.86% in 2024, then skyrocketed by 47bps to 2121.14% in 2025.
  • Per Business Quant, the three most recent readings for SKVI's EBITDA Margin are 2121.14% (Q3 2025), 2724.74% (Q2 2025), and 2797.04% (Q1 2025).